Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, Criscitiello C, Lynce F, Woodward WA, Curigliano G. Valenza C, et al. Among authors: reduzzi c. Eur J Cancer. 2024 Oct 28;213:115097. doi: 10.1016/j.ejca.2024.115097. Online ahead of print. Eur J Cancer. 2024. PMID: 39486164
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.
Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM, Jantus-Lewintre E, Fusco N, Malapelle U, Gandara DR, Rolfo C, Serrano MJ, Cristofanilli M; International Society of Liquid Biopsy (ISLB). Reduzzi C, et al. Crit Rev Oncol Hematol. 2024 Nov;203:104483. doi: 10.1016/j.critrevonc.2024.104483. Epub 2024 Aug 17. Crit Rev Oncol Hematol. 2024. PMID: 39159706 Review.
Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA.
Zhang Q, Cai Z, Gerratana L, Davis AA, D'Amico P, Chawla A, Jacob S, Zhang Y, Jiao J, Qin W, Reduzzi C, Flaum L, Shah A, Gradishar WJ. Zhang Q, et al. Among authors: reduzzi c. Clin Cancer Res. 2024 Aug 15;30(16):3470-3480. doi: 10.1158/1078-0432.CCR-24-0535. Clin Cancer Res. 2024. PMID: 38829582
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: reduzzi c. Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. Breast Cancer Res. 2023. PMID: 37784176 Free PMC article.
42 results